A Phase 3 interventional study of Nintedanib in Idiopathic Pulmonary Fibrosis, sponsored by Boehringer Ingelheim. Completed at 173 sites in 24 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2022-03-25.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis — 1 open to participants now, 1 under way, none of them phase 3. nintedanib · Idiopathic Pulmonary Fibrosis.
Among the 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis, this one has the largest enrollment, is the only one that started in 2012, is one of 2 in phase 3, and was the 2nd registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →1 of the 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis is open now. Recruiting first, the newest first:
First Affiliated Hospital of Wenzhou Medical University
Ages 40+
nintedanib: first FDA approval 2014 (OFEV), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2012.
This study's enrollment of 752 is above the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 49 across the 16 interventional studies. Of the 15 that completed or were terminated, 8 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 16 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim: 1 open now, 3 under way, 1 of them phase 3. Of 31 finished, 26 (84%) have results posted.
Among the 36 studies in Idiopathic Pulmonary Fibrosis by Boehringer Ingelheim, this one is the 3rd largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2012, is one of 5 in phase 3, and was the 2nd registered.
Boehringer Ingelheim’s Idiopathic Pulmonary Fibrosis studies by the year they started, since 2010.
1 of the studies testing nintedanib in Idiopathic Pulmonary Fibrosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07583589First Affiliated Hospital of Wenzhou Medical UniversityNintedanib With or Without Dextromethorphan in Patients With Idiopathic Pulmonary Fibrosis (IPF) | 2027-03-01 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 36 in Idiopathic Pulmonary Fibrosis:
This tab as a report to print or save as PDF → With an account.
The aim of this extension trial is to assess the long-term safety of BIBF 1120 treatment in patients with Idiopathic Pulmonary Fibrosis who have completed one year treatment and the follow up period in the double-blind phase III placebo controlled parent trials (1199.32 and 1199.34), who wish to continue treatment with BIBF 1120.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patient to receive a capsule containing Nintedanib twice a day
Drug: Nintedanib
Nintedanib twice a day
Also known as: BIBF 1120
Incidence of Adverse Events (AEs)
This is the measure for percentage of patients with adverse events (AEs) observed during the trial. The incidence of adverse events (% of patients) over the course of the trial, including the incidence of serious AEs, AEs leading to discontinuation, and fatal AEs are presented.
Time frame: From first drug administration until end of treatment period + 28 days, in total up to 56.3 months plus 28 days.
This was a prospective, open-label extension trial in which patients with Idiopathic pulmonary fibrosis (IPF), who had completed 52 weeks of treatment and the follow-up period in the randomised, double-blind, placebo-controlled parent trials 1199.32(NCT01335464)/.34(NCT01335477) and who needed access to nintedanib outside of the discontinued parent trials 1199.35(NCT01170065)/.187(NCT01979952).
| Milestone | Total (1199.32/.34/.35/.187) |
|---|---|
| Started | 752 |
| Treated | 751 |
| Completed | 227 |
| Not completed | 525 |
| Withdrew: Adverse event | 231 |
| Withdrew: Protocol violation | 4 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Withdrawal by subject | 45 |
| Withdrew: Other than specified | 96 |
| Withdrew: Not treated | 1 |
| Withdrew: Death | 145 |
This is the measure for percentage of patients with adverse events (AEs) observed during the trial. The incidence of adverse events (% of patients) over the course of the trial, including the incidence of serious AEs, AEs leading to discontinuation, and fatal AEs are presented.
| Percentage of patients (%) | Total (1199.32/.34) |
|---|---|
| Any AEs | 98.5 |
| AEs leading to discontinuation of trial drug | 42.6 |
| Serious AEs | 68.9 |
| Fatal AEs | 23.8 |
Collected over From first drug administration in this study until 28 days after the last drug, up to 7.5 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Total (1199.32/.34) | 182/734 (24.8%) | 509/734 (69.3%) | 671/734 (91.4%) |
| Placebo (1199.32/.34) | 78/304 (25.7%) | 208/304 (68.4%) | 281/304 (92.4%) |
| Nintedanib 150 Bid (1199.32/.34) | 104/430 (24.2%) | 301/430 (70%) | 390/430 (90.7%) |
| Placebo (1199.187) | 0/7 (0%) | 0/7 (0%) | 3/7 (42.9%) |
| Nintedanib 100 Bid (1199.35) | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| Nintedanib 150 Bid (1199.35/.187) | 0/8 (0%) | 1/8 (12.5%) | 2/8 (25%) |
| Total (1199.35/.187) | 0/17 (0%) | 1/17 (5.9%) | 6/17 (35.3%) |
| Total (1199.32/.34/.35/.187) | 182/751 (24.2%) | 510/751 (67.9%) | 677/751 (90.1%) |
| Event | Total (1199.32/.34) | Placebo (1199.32/.34) | Nintedanib 150 Bid (1199.32/.34) | Placebo (1199.187) | Nintedanib 100 Bid (1199.35) | Nintedanib 150 Bid (1199.35/.187) | Total (1199.35/.187) | Total (1199.32/.34/.35/.187) |
|---|---|---|---|---|---|---|---|---|
| Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 153/734 | 64/304 | 89/430 | 0/7 | 0/2 | 0/8 | 0/17 | 153/751 |
| PneumoniaInfections and infestations | 99/734 | 40/304 | 59/430 | 0/7 | 0/2 | 0/8 | 0/17 | 99/751 |
| CholelithiasisHepatobiliary disorders | 9/734 | 4/304 | 5/430 | 0/7 | 0/2 | 1/8 | 1/17 | 10/751 |
| Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders | 48/734 | 22/304 | 26/430 | 0/7 | 0/2 | 0/8 | 0/17 | 48/751 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 35/734 | 9/304 | 26/430 | 0/7 | 0/2 | 0/8 | 0/17 | 35/751 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 38/734 | 16/304 | 22/430 | 0/7 | 0/2 | 0/8 | 0/17 | 38/751 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 17/734 | 11/304 | 6/430 | 0/7 | 0/2 | 0/8 | 0/17 | 17/751 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 13/734 | 9/304 | 4/430 | 0/7 | 0/2 | 0/8 | 0/17 | 13/751 |
| Respiratory tract infectionInfections and infestations | 13/734 | 8/304 | 5/430 | 0/7 | 0/2 | 0/8 | 0/17 | 13/751 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 15/734 | 4/304 | 11/430 | 0/7 | 0/2 | 0/8 | 0/17 | 15/751 |
| Event | Total (1199.32/.34) | Placebo (1199.32/.34) | Nintedanib 150 Bid (1199.32/.34) | Placebo (1199.187) | Nintedanib 100 Bid (1199.35) | Nintedanib 150 Bid (1199.35/.187) | Total (1199.35/.187) | Total (1199.32/.34/.35/.187) |
|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 514/734 | 213/304 | 301/430 | 2/7 | 0/2 | 0/8 | 2/17 | 516/751 |
| InfluenzaInfections and infestations | 35/734 | 11/304 | 24/430 | 0/7 | 1/2 | 0/8 | 1/17 | 36/751 |
| CoughRespiratory, thoracic and mediastinal disorders | 166/734 | 66/304 | 100/430 | 0/7 | 0/2 | 0/8 | 0/17 | 166/751 |
| NauseaGastrointestinal disorders | 146/734 | 70/304 | 76/430 | 0/7 | 0/2 | 0/8 | 0/17 | 146/751 |
| BronchitisInfections and infestations | 145/734 | 54/304 | 91/430 | 0/7 | 0/2 | 0/8 | 0/17 | 145/751 |
| NasopharyngitisInfections and infestations | 152/734 | 62/304 | 90/430 | 0/7 | 0/2 | 0/8 | 0/17 | 152/751 |
| Weight decreasedInvestigations | 123/734 | 63/304 | 60/430 | 0/7 | 0/2 | 0/8 | 0/17 | 123/751 |
| Decreased appetiteMetabolism and nutrition disorders | 104/734 | 58/304 | 46/430 | 0/7 | 0/2 | 0/8 | 0/17 | 104/751 |
| Upper respiratory tract infectionInfections and infestations | 109/734 | 38/304 | 71/430 | 0/7 | 0/2 | 0/8 | 0/17 | 109/751 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 118/734 | 48/304 | 70/430 | 0/7 | 0/2 | 1/8 | 1/17 | 119/751 |
Treated set (TS): The data set consisted of all patients who were dispensed trial medication and were documented to have taken at least one dose, and had participated in 1199.32/.34 parent trials.
| Age, Continuous(Years) | Total (1199.32/.34) |
|---|---|
| Mean | 67.2 ± 7.8 |
| Sex: Female, Male(Participants) | Total (1199.32/.34) |
|---|---|
| Female | 147 |
| Male | 587 |
| Race (NIH/OMB)(Participants) | Total (1199.32/.34) |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 214 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 431 |
| More than one race | 0 |
| Unknown or Not Reported | 86 |
Showing the first 100 of 173 sites across 24 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2012 to primary completion in Jul 2017, 60 months.
Results were first posted in Jul 2018, 1 year after primary completion.
Of 24 phase 3 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 60. This study's 60 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nintedanib
Idiopathic Pulmonary Fibrosis →